Your Brain on Ozempic: The Full Investigation

What the free newsletter didn't cover. And why it matters more.

If you read Monday’s case file, you know the basic story.

GLP-1 receptors in the nucleus accumbens. Dopamine signals getting quieter. People losing cravings for alcohol, nicotine, and gambling without anyone telling them it would happen.

That’s the headline. This is everything underneath it

What the research actually shows

The 2024 Lancet Psychiatry trial is the one everyone cites, but most people stop at the 28% relapse reduction number and move on. The more interesting finding is buried further in the data.